latest news releases from the newsroom
Sports-Stuff Announces Sponsorship Deal With Online Gaming Giant BetCRIS
VANCOUVER, British Columbia, May 19, 2006 (PRIMEZONE) -- Sports-Stuff.com Inc. (Pink Sheets:SSUF) (Frankfurt:S5F), a publisher and distributor of SMS alerts, mobile web sites, ringtones and mobile video games for the sports and entertainment industry, announced today that BetCRIS will sponsor Sport-Stuff's real-time news and scoring alerts and make them available to their client base.
W2 Energy Inc.
W2 Energy Inc. Receives Off-Take Request for Organic Fertilizer Product
NEW YORK, May 19, 2006 (PRIMEZONE) -- W2 Energy Inc. (Pink Sheets:WWEN), a developer of green energy, is pleased to announce it has received letters of request for off-take of our fertilizer product. The organic fertilizer which is a co-product produced in the W2 "GAT" reactor will be pelletized and sold in bulk for $US200 per ton. The 10,000 barrel per day plant produces approximately 255,000 tons of organic fertilizer per year, bringing an additional $51M in sales, combined with the diesel fuel at $204M and $55M in electricity generation, producing a yearly sales number of $310.5M per 10,000 bpd plant. Combined with the need to construct seven plants to satisfy production requests for the diesel product, W2 now has requests for product totaling $2.17B US.
MDwise to Expand Statewide to Serve Hoosier Healthwise Beneficiaries
INDIANAPOLIS, May 19, 2006 (PRIMEZONE) -- MDwise, an Indiana-based, provider-sponsored, not-for-profit managed care organization, announced its intent to bid on the State's Hoosier Healthwise Medicaid program as a statewide bidder, expanding far beyond its current service areas in central and northwest Indiana.
Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. Announces a Key New Member Joins Management
PHOENIX, May 19, 2006 (PRIMEZONE) -- Synovics Pharmaceuticals, Inc. (OTCBB:SYVC), a specialty pharmaceutical company with proprietary drug formulation and delivery technologies utilized in the development of a pipeline of difficult to formulate, oral controlled-release, generic and branded drugs, announced today that Theodore Miro has joined its subsidiary, Synovics Laboratories, Inc., as Vice President responsible for technical operations. In this role he will lead in the development of Synovics' drug pipeline and will interface with Kirk Pharmaceuticals, Synovics announced pending acquisition, in the development and manufacture of the Company's products. Mr. Miro has previously worked for Forrest Labs, Barr Labs and Pfizer.
Parker Waichman Alonso LLP
Parker & Waichman, LLP Files Suit Against Ortho-McNeil Pharmaceutical, Inc. on Behalf of 33-Year-Old Woman Diagnosed with Bilateral Pulmonary Embolism and Deep Venous Thrombosis After Using Ortho Evra Birth Control Patch for Two Months -- JNJ
NEW YORK, May 19, 2006 (PRIMEZONE) -- Parker & Waichman, LLP (www.yourlawyer.com) announced that it has filed suit against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc. (NYSE:JNJ), on behalf of a 33-year-old woman and her husband. The woman suffered a bilateral pulmonary embolism and deep venous thrombosis (DVT) after using Ortho Evra for two months. The suit was filed in the United States District Court for the District of New Jersey in Newark, New Jersey. For more information on Ortho Evra and this case, please visit www.orthopatchlawsuit.com or www.yourlawyer.com/topics/overview/Ortho_Evra_Patch
Scott+Scott, LLC Files Class Action Lawsuit Against UnitedHealth Group Inc. on Behalf of Investors -- UNH
COLCHESTER, Conn., May 19, 2006 (PRIMEZONE) -- On May 19, 2006, Scott+Scott, LLC, filed a class action against UnitedHealth Group, Inc. ("UnitedHealth" or the "Company") (NYSE:UNH) and certain officers in the U.S. District Court for the District of Minnesota. The action is on behalf of UnitedHealth securities purchasers during the period May 4, 2001 through April 7, 2006, inclusive (the "Class Period"), for securities law violations. The complaint alleges that defendants made false and misleading statements and material omissions regarding the Company's executive compensation practices, including the backdating of stock option grants. As a result, the price of the Company's securities was inflated during the Class Period, thereby harming investors.